Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. A compound represented by Formula (I):wherein Z1 is C(R4) or the like； R4 is a hydrogen atom or the like； Z2 is C(R5a)(R5a') or the like； the dashed line represents the presence or absence of a bond； when the dashed line represents the presence of a bond, then R5a' is absent； R5a and R5a' are each independently a hydrogen atom or the like； Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like； Y1 is O or the like； R2a is a group represented by the formula: -(C(R2a')(R2b'))n-R1； R2b is a hydrogen atom or the like； R2a' and R2b' is each independently a hydrogen atom or the like； R1 is substituted or unsubstituted aromatic carbocyclyl or the like； X is N(R7a) or the like； R7a is a hydrogen atom or the like； R3 is substituted or unsubstituted aromatic carbocyclyl or the like； n is an integer from 0 to 4； and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.
